4:09 PM ET
8-K
Stock Buyback
Keros Therapeutics Announces $5M Stock Buyback
Keros Therapeutics announced that its Board of Directors approved a new $5 million share repurchase program for its common stock. The buyback authorization follows the company's receipt of a $20 million development milestone payment from Takeda Pharmaceuticals related to the clinical trial dosing of elritercept. Keros expects its current cash reserves, including this milestone, to fund operations into 2029.
- Value
- $5M